Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Investor logo

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SALEK Cyril HRABOVSKÝ Štěpán FOLBER František KORISTEK Zdenek HORACEK Jan M FRONKOVA Eva REZNICKOVA Leona Rezkova PECHERKOVA Pavla SOUKUP Petr DLUHOSOVA Barbora POLIVKOVA Vaclava KRIZKOVA Jitka MACHOVA POLAKOVA Katerina VRZALOVÁ Zuzana HALÁMOVA Hana TRKA Jan CETKOVSKY Petr DOUBEK Michael

Year of publication 2025
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Faculty of Medicine

Citation
web https://haematologica.org/article/view/11946
Doi https://doi.org/10.3324/haematol.2024.287062
Keywords Blinatumomab; acute lymphoblastic leukemia; Ph- B-cell precursor
Attached files
Description Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. In the MRD setting, blinatumomab induced MRD negativity (MRDneg) in 78% of patients, with 85% achieving MRD <10-. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces risk of relapse.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info